Kinases are the major anticancer drug target class of the 21st century1 with nearly 60 small molecule kinase inhibitors approved for clinical use in the first two decades. Key to the success of kinase inhibitor therapy has been the simultaneous development of biomarker assays to enable the selection of patients most likely to respond in the clinic.

Cancer cell panel profiling is the parallel testing of compounds on a large panel of cancer cell lines. By correlating drug sensitivity with genomic information of the cell lines, novel predictive drug response biomarkers can be identified.

In this webinar, Dr. Guido Zaman, managing director, and Jeffrey Kooijman, bioinformatician at NTRC, present the cancer cell panel profiling of all twenty kinase inhibitors approved for clinical use in cancer therapy between 2018 and 2020, as NTRC scientists have done previously for all FDA approved kinase inhibitors through May 20182,3. The webinar focuses on a comparison of cancer cell panel profiles of the newly approved kinase inhibitors to clinical stage and preclinical competitors. In addition, the researchers present how predictive drug response markers were identified for patient stratification, which were used to determine the targeting of hot spot cancer mutations.

What You Will Learn:

  • Biochemical kinase profiling and cancer cell panel profiling and how they compare
  • How to identify predictive drug response biomarkers by cancer cell panel profiling
  • Comparative cancer cell panel profiling of different kinase inhibitors binding to the same target

Speakers

Dr. Guido Zaman, Managing Director and Head of Biology, NTRC

Jeffrey Kooijman, Bioinformatician, NTRC

For questions, contact: [email protected]

Access the Webinar

  • This field is for validation purposes and should be left unchanged.

About NTRC
NTRC is a precision medicine company in oncology and cancer immunotherapy. Clients are clinical and preclinical biopharma companies that seek differentiation for their drugs and drug candidates. Using the Oncolines™ cancer cell line panel and GeneNominator™ gene expression platform, drug response biomarkers and new disease indications are identified. With SynergyFinder™ and SynergyScreen™, new drug combinations are discovered. To investigate the mechanism of action of compounds, NTRC can perform gene and protein expression analysis, DNA and RNA sequencing, and flow cytometry. Using an extensive reference compound database, NTRC scientists can help to discriminate a client compound from competitor’s compounds.

NTRC represents Carna Biosciences, Inc. (Kobe, Japan) for biochemical kinase profiling in Europe and Israel. Carna exclusively represents NTRC in Japan.

  1. Cohen P. Protein kinases — The major drug targets of the 21st century? Nat Rev Drug Discov. 2002;1:309-15.
  2. Uitdehaag JCM, de Roos JADM, van Doornmalen AM, Prinsen MBW, de Man J, Tanizawa Y, et al. Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS ONE. 2014;9:e92146.
  3. Uitdehaag JCM, Kooijman JJ, de Roos JADM, Prinsen MBW, Dylus J, Willemsen-Seegers N, et al. Combined cellular and biochemical profiling to identify drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Mol Cancer Ther. 2019;18:470-81.